Show Notes
N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Iofina reports record year as CEO discusses results with Zak Mir
Zak Mir talks to Dr Tom Becker, President & CEO, Iofina, in the wake of the spe -
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, in the wake of recen -
Powerhouse Energy CEO talks strategy and recent developments
Zak Mir talks to Paul Emmitt, CEO Powerhouse Energy (AIM: PHE), as the company -
Winterflood Securities, Liquidity, Retail Fundraising & the London Market Outlook
Zak Mir talks to Andrew Stancliffe, Head of Execution Services at Winterflood S